Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection

Table 7

Results of the subgroup analysis for the endpoints: inpatient bed-days per patient and year, number of hospitalisations per patient and year, and hospital costs per patient and year. Results are presented for previous therapy subgroups containing more than 5 patients.

Endpoints	Before initiation		After initiation		Difference
	Mean (SE)	95% CI	Mean (SE)	95% CI	Mean (SE)	95% CI
Inpatient bed-days per patient-year
Atypical oral only (𝑁=129)	61.63 (4.30)	(53.20; 70.05)	37.69 (6.03)	(25.87; 49.51)	−23.94 (7.21)	(−38.07; −9.81)
Atypical oral Combination (𝑁=32)	70.76 (12.80)	(45.67; 95.86)	38.95 (13.27)	(12.95; 64.95)	−31.81 (14.35)	(−59.93; −3.98)
Untreated (𝑁=9)	50.06 (15.94)	(18.82; 81.30)	17.8 (6.65)	(4.77; 30.84)	−32.26 (16.19)	(−63.99; −0.54)
No. hospitalizations per patient-year
Atypical oral only (𝑁=129)	0.9 (0.06)	(0.80; 1.01)	0.69 (0.09)	(0.51; 0.86)	−0.22 (0.09)	(−0.40; −0.03)
Atypical oral Combination (𝑁=32)	0.96 (0.14)	(0.69; 1.24)	0.78 (0.23)	(0.32; 1.24)	−0.18 (0.17)	(−0.51; 0.15)
Untreated (𝑁=9)	1.18 (0.30)	(0.59; 1.78)	0.41 (0.14)	(0.13; 0.68)	−0.77 (0.29)	(−1.34; −0.21)
Hospital costs per patient-year, €
Atypical oral only (𝑁=129)	27,560 (1,934)	(23,770; 31,351)	16,177 (2,546)	(11,187; 21,167)	−11,383 (3,007)	(−17,276; −5,491)
Atypical oral Combination (𝑁=32)	32,415 (5,439)	(21,755; 43,075)	15,666 (5,027)	(5,812; 25,519)	−16,749 (6,782)	(−30,041; −3,457)
Untreated (𝑁=9)	20,561 (6,633)	(7,561; 33,562)	8,435 (3,379)	(1,812; 15,059)	−12,126 (7,735)	(−27,28; 3,035)